Cargando…
Corrigendum: Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10325674/ https://www.ncbi.nlm.nih.gov/pubmed/37427117 http://dx.doi.org/10.3389/fonc.2023.1233247 |
| _version_ | 1785069271627333632 |
|---|---|
| author | Liu, Jun-Ning Li, Ji-Jiang Yan, Shu Zhang, Guang-Nian Yi, Peng-Sheng |
| author_facet | Liu, Jun-Ning Li, Ji-Jiang Yan, Shu Zhang, Guang-Nian Yi, Peng-Sheng |
| author_sort | Liu, Jun-Ning |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10325674 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Frontiers Media S.A. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-103256742023-07-07 Corrigendum: Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis Liu, Jun-Ning Li, Ji-Jiang Yan, Shu Zhang, Guang-Nian Yi, Peng-Sheng Front Oncol Oncology Frontiers Media S.A. 2023-06-22 /pmc/articles/PMC10325674/ /pubmed/37427117 http://dx.doi.org/10.3389/fonc.2023.1233247 Text en Copyright © 2023 Liu, Li, Yan, Zhang and Yi https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| spellingShingle | Oncology Liu, Jun-Ning Li, Ji-Jiang Yan, Shu Zhang, Guang-Nian Yi, Peng-Sheng Corrigendum: Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis |
| title | Corrigendum: Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis |
| title_full | Corrigendum: Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis |
| title_fullStr | Corrigendum: Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis |
| title_full_unstemmed | Corrigendum: Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis |
| title_short | Corrigendum: Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis |
| title_sort | corrigendum: transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis |
| topic | Oncology |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10325674/ https://www.ncbi.nlm.nih.gov/pubmed/37427117 http://dx.doi.org/10.3389/fonc.2023.1233247 |
| work_keys_str_mv | AT liujunning corrigendumtransarterialchemoembolizationcombinedwithlenvatinibversustransarterialchemoembolizationcombinedwithsorafenibforunresectablehepatocellularcarcinomaasystematicreviewandmetaanalysis AT lijijiang corrigendumtransarterialchemoembolizationcombinedwithlenvatinibversustransarterialchemoembolizationcombinedwithsorafenibforunresectablehepatocellularcarcinomaasystematicreviewandmetaanalysis AT yanshu corrigendumtransarterialchemoembolizationcombinedwithlenvatinibversustransarterialchemoembolizationcombinedwithsorafenibforunresectablehepatocellularcarcinomaasystematicreviewandmetaanalysis AT zhangguangnian corrigendumtransarterialchemoembolizationcombinedwithlenvatinibversustransarterialchemoembolizationcombinedwithsorafenibforunresectablehepatocellularcarcinomaasystematicreviewandmetaanalysis AT yipengsheng corrigendumtransarterialchemoembolizationcombinedwithlenvatinibversustransarterialchemoembolizationcombinedwithsorafenibforunresectablehepatocellularcarcinomaasystematicreviewandmetaanalysis |